

**FORM 51-102F3**  
**MATERIAL CHANGE REPORT**

**Item 1: Name and Address of Reporting Issuer**

Cannvas MedTech Inc. (the “Company” or “Cannvas MedTech”)  
804-750 West Pender Street  
Vancouver, BC V6C 2T7

**Item 2: Date of Material Change**

January 21, 2019 and January 25, 2019.

**Item 3: News Release**

News releases were disseminated on January 21, 2019 and January 28, 2019 and filed on SEDAR ([www.sedar.com](http://www.sedar.com)).

**Item 4: Summary of Material Changes**

The Company continues toward its goal of becoming the leading social and census data collection agency of the cannabis industry. Cannvas is well-positioned to accelerate its data collection and analysis within the industry.

Additionally, the Company announced the issuance of shares for debt and shares pursuant to milestones and the appointment of the first member of its scientific advisory board.

**Item 5: Full Description of Material Change**

On January 21, 2019, the Company continues toward its goal of becoming the leading social and census data collection agency of the cannabis industry. Cannvas is well-positioned to accelerate its data collection and analysis within the industry.

Cannvas Data uses machine-learning algorithms and artificial intelligence (AI) to analyze cannabis industry trends, opportunities and challenges and create detailed reports for a range of sectors including education, medical and health sciences, government and the cannabis sector itself. Through the partnership network established by Cannvas.Me with recognized healthcare and education providers, such as Namaste, Hi-Jane and Advica Health, Cannvas Data is increasing the amount of data it processes nearly every day. The result is an ongoing anonymized analysis of what cannabis consumers across Canada are seeking out, from education and methods of ingestion to products, producers and prescriptions.

Through Cannvas Health, the Company has entered into agreements with leading health care and education organizations, as well as dispensaries and cannabis brands, to provide white label solutions for digital cannabis education opportunities powered by the Cannvas.Me platform.

Cannvas MedTech also recently joined the Global Cannabis Partnership (GCP), a collective of leaders in the government-sanctioned, adult-use recreational cannabis industry, as a Member organization. The goal of the GCP is to develop an international standard for the safe and responsible production, distribution and consumption of legal recreational cannabis and help shape the face of social responsibility in the cannabis industry. Its main objectives are to build credibility for government agencies, industry and partners through responsible practices, align and leverage common principles and practices across diverse jurisdictions, and help partners mitigate negative impacts and leverage best practices from within and outside the industry to protect and enhance social licence to operate, with a view to minimizing harm.

Additionally, the Company issued a total of 58,703 common shares (the “Shares”) at a deemed value of \$0.30 per Share to certain persons for certain consulting fees owed totaling approximately \$17,610.90. Cannvas also issued an aggregate of 1,000,000 Shares of the Company at a deemed value of \$0.30 per Share to certain related parties of the Company, pursuant to the achievement of certain milestones and in accordance with their respective consulting agreements.

On January 28, 2019, the Company announced the first appointee to its newly-formed Cannabis Sciences Advisory Board, providing independent scientific oversight and original content for the Cannvas.Me cannabis education platform. Angela Smith, PhD, joins Cannvas as the Board lead, bringing with her a wealth of experience in medical, scientific and clinical affairs for Canadian medicinal and recreational cannabis brands and natural health products, and leading international food brands.

The Cannabis Sciences Advisory Board is an independent panel of esteemed and established scientific consultants from across a range of industries providing oversight and original content to the Cannabis.Me digital cannabis education platform. As the first appointee, Angela will lead the Board's activities in determining in which areas of current cannabis scientific research to focus its efforts while leveraging her past experience coordinating and managing medical expert advisory boards to develop the structure of the Board's contributions, activities and inquiries.

A PhD-level scientist with over a decade of experience in basic and clinical research and teaching, and expert knowledge in regulatory, medical, scientific, and technical affairs, Angela is the founder of Catalyst Life Sciences Consulting, a boutique firm providing a wide range of medical, scientific and regulatory consulting services for Canadian natural health products, highly regulated food products including infant formulas and foods, and medical and recreational cannabis. She brings with her a strong working knowledge of North American and international regulatory frameworks, including the Federal Cannabis Act and Provincial/Territorial cannabis regulatory frameworks.

Angela spent 10 years in the food and natural health products industry, leading and supporting prenatal, maternal and infant scientific affairs. Her expertise included the preparation of evidence-based regulatory documentation and scientific evidence, coordination, development and evaluation of educational program initiatives for healthcare professionals and consumers, and providing scientific expertise and evidence-based guidance to senior executives.

Angela has worked on projects with the University of Toronto, Toronto's Hospital for Sick Children and B.C. Women's and Children's Hospital, among others. Angela has amassed a great deal of experience developing and managing medical and continuing education programs for healthcare professionals through organizations including the College of Family Physicians of Canada, the Royal College of Physicians and Surgeons of Canada and the Canadian Council on Continuing Education in Pharmacy. Over her career she has also made valuable contributions to stakeholder consultations on health policies and position statements with the federal government, expert groups and associations.

Operating independent of any licenced producers or clinics, Cannabis.Me works with its Medical Advisory Board and Educational Advisory Panel and newly-formed Cannabis Sciences Advisory Board to provide a safe space for cannabis education with no pressure to purchase or consume.

The Cannabis Sciences Advisory Board will consist of prominent Canadians and Americans who are among the leaders in their fields with robust backgrounds in education, health sciences, medicine and research. Members of the Board will be in constant communication with the Cannabis.Me team to offer guidance on new educational modules, oversight of and contributions to original Cannabis.Me content, and insights into health sciences, clinical trials, medical, scientific and regulatory affairs, and other related topics.

Additionally, the company issued a total of 487,500 Shares at a deemed value of \$0.30 per share to certain persons and a related party for fees owed totaling approximately \$146,250.

**Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**Item 7: Omitted Information**

None.

**Item 8: Executive Officer**

For further information, please contact:

**CannvasMedTech.com**

Investor Relations  
Renmark Financial Communications Inc.  
Shushu Feng: [sfeng@renmarkfinancial.com](mailto:sfeng@renmarkfinancial.com)  
Tel: (416) 644-2020 or (212) 812-7680

**Item 9: Date of Report**

January 29, 2019.